Craft

Fresenius

Stock Price

€34.1

2024-10-29

Market Capitalization

€18.5 B

2024-08-26

Revenue

€22.3 B

FY, 2023

Fresenius Summary

Company Summary

Overview
Fresenius is a healthcare group offering products and services for dialysis, hospitals, and outpatient treatment. It comprises the operating companies Fresenius Kabi and Fresenius Helios and the investment companies Fresenius Medical Care and Fresenius Vamed. Fresenius Kabi specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. Fresenius Helios is a private healthcare provider. Fresenius Medical Care offers products and services for individuals with renal diseases. Fresenius Vamed delivers services for hospitals and other healthcare facilities.
Type
Public
Status
Active
Founded
1912
HQ
Bad Homburg vor der Höhe, DE | view all locations
Website
https://www.fresenius.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Michael Sen

    Michael Sen, Chairman of the Management Board

  • Sara Hennicken

    Sara Hennicken, Chief Financial Officer

  • Pierluigi Antonelli

    Pierluigi Antonelli, CEO, Fresenius Kabi

  • Helen Giza

    Helen Giza, CEO, Fresenius Medical Care

Operating MetricsView all

Treatments

52M
1.9%

FY, 2022

Patients

24M
9.1%

FY, 2022

Dialysis Centers

4.1K
1.3%

FY, 2022

LocationsView all

100 locations detected

  • Bad Homburg vor der Höhe, HE HQ

    Germany

    Else-Kröner-Straße 1

  • Lake Zurich, IL

    United States

    3 Corporate Dr

  • Waltham, MA

    United States

    920 Winter St

  • Buenos Aires, CABA

    Argentina

    Arenales 707, 3° piso

  • Buenos Aires, CABA

    Argentina

    Av. Cabildo 2677 Piso 10

  • Sydney, NSW

    Australia

    L17, 61 Lavender Street, Milsons Point

and 94 others

Fresenius Financials

Summary Financials

Revenue (Q3, 2024)
€5.4B
Gross profit (Q3, 2024)
€1.6B
Net income (Q3, 2024)
€319.0M
Cash (Q3, 2024)
€1.5B
EBIT (Q3, 2024)
€531.0M
Enterprise value
$30.3B

Footer menu